A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Enrolling by invitation · NCT06115642 · Registry updated 2026-05-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors | Advanced/Metastatic Malignant Solid Tumors | Enrolling by invitation | Phase 1 | 2026-05-29 | NCT06115642 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Henlius Biotech | 58 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer hospital, Chinese Academy of Medical Sciences | Beijing | China | 12 |
| Georgetown University | Washington D.C. | United States | 21 |
| Kindai University Hospital | Sayama | Japan | 8 |
| MD Anderson Medical Center | Houston | United States | 1 |
| National Cancer Center Hospital | Tokyo | Japan | 42 |
| Okayama University Hospital | Okayama | Japan | 75 |
| Sendai Kousei Hospital | Sendai | Japan | 11 |
| Shizuoka Cancer Center | Shizuoka | Japan | 19 |
| Stanford University | Stanford | United States | 213 |
| Xiangya Hospital Central South University | Changsha | China | 1 |